BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Resik S, Tejeda A, Lago P, Diaz M, Carmenates A, Sarmiento L, Alemañi N, Galindo B, Burton A, Friede M, Landaverde M, Sutter R. Randomized Controlled Clinical Trial of Fractional Doses of Inactivated Poliovirus Vaccine Administered Intradermally by Needle‐Free Device in Cuba. J INFECT DIS 2010;201:1344-52. [DOI: 10.1086/651611] [Cited by in Crossref: 101] [Cited by in F6Publishing: 79] [Article Influence: 9.2] [Reference Citation Analysis]
Number Citing Articles
1 Dietrich J, Andreasen LV, Andersen P, Agger EM. Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01. PLoS One 2014;9:e100879. [PMID: 24956110 DOI: 10.1371/journal.pone.0100879] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
2 Pagliusi S, Leite LC, Datla M, Makhoana M, Gao Y, Suhardono M, Jadhav S, Harshavardhan GV, Homma A. Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all. Vaccine 2013;31 Suppl 2:B176-83. [PMID: 23598479 DOI: 10.1016/j.vaccine.2012.11.060] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
3 Saitoh A, Aizawa Y. Intradermal vaccination for infants and children. Hum Vaccin Immunother 2016;12:2447-55. [PMID: 27135736 DOI: 10.1080/21645515.2016.1176652] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
4 Chen Z, Chumakov K, Dragunsky E, Kouiavskaia D, Makiya M, Neverov A, Rezapkin G, Sebrell A, Purcell R. Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis. J Virol 2011;85:4354-62. [PMID: 21345966 DOI: 10.1128/JVI.02553-10] [Cited by in Crossref: 33] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
5 Kim YC, Jarrahian C, Zehrung D, Mitragotri S, Prausnitz MR. Delivery systems for intradermal vaccination. Curr Top Microbiol Immunol 2012;351:77-112. [PMID: 21472533 DOI: 10.1007/82_2011_123] [Cited by in Crossref: 36] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
6 Resik S, Tejeda A, Mach O, Fonseca M, Diaz M, Alemany N, Garcia G, Hung LH, Martinez Y, Sutter R. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine 2015;33:307-13. [PMID: 25448109 DOI: 10.1016/j.vaccine.2014.11.025] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
7 Thomassen YE, Bakker WA. sIPV process development for costs reduction. Vaccine 2015;33:4307-12. [DOI: 10.1016/j.vaccine.2015.03.076] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Zaman K, Estívariz CF, Morales M, Yunus M, Snider CJ, Gary HE Jr, Weldon WC, Oberste MS, Wassilak SG, Pallansch MA, Anand A. Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial. Lancet Infect Dis 2018;18:657-65. [PMID: 29571817 DOI: 10.1016/S1473-3099(18)30113-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
9 Mahmood K, Pelkowski S, Atherly D, Sitrin RD, Donnelly JJ. Hexavalent IPV-based combination vaccines for public-sector markets of low-resource countries. Hum Vaccin Immunother. 2013;9:1894-1902. [PMID: 23787559 DOI: 10.4161/hv.25407] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
10 Mashunye TR, Ndwandwe DE, Dube KR, Shey M, Shelton M, Wiysonge CS. Fractional dose compared with standard dose inactivated poliovirus vaccine in children: a systematic review and meta-analysis. Lancet Infect Dis 2021;21:1161-74. [PMID: 33939958 DOI: 10.1016/S1473-3099(20)30693-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Herzog C. Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature. Expert Review of Vaccines 2014;13:399-415. [DOI: 10.1586/14760584.2014.883285] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
12 Bandyopadhyay AS, Gast C, Rivera L, Sáez-Llorens X, Oberste MS, Weldon WC, Modlin J, Clemens R, Costa Clemens SA, Jimeno J, Rüttimann R. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial. Lancet Infect Dis 2021;21:559-68. [PMID: 33284114 DOI: 10.1016/S1473-3099(20)30555-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Resik S, Tejeda A, Mach O, Sein C, Molodecky N, Jarrahian C, Saganic L, Zehrung D, Fonseca M, Diaz M, Alemany N, Garcia G, Hung LH, Martinez Y, Sutter RW. Needle-free jet injector intradermal delivery of fractional dose inactivated poliovirus vaccine: Association between injection quality and immunogenicity. Vaccine 2015;33:5873-7. [PMID: 26192350 DOI: 10.1016/j.vaccine.2015.06.071] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
14 Estívariz CF, Pallansch MA, Anand A, Wassilak SG, Sutter RW, Wenger JD, Orenstein WA. Poliovirus vaccination options for achieving eradication and securing the endgame. Current Opinion in Virology 2013;3:309-15. [DOI: 10.1016/j.coviro.2013.05.007] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
15 Snider CJ, Zaman K, Estivariz CF, Yunus M, Weldon WC, Wannemuehler KA, Oberste MS, Pallansch MA, Wassilak SG, Bari TIA, Anand A. Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial. Lancet 2019;393:2624-34. [PMID: 31104832 DOI: 10.1016/S0140-6736(19)30503-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Soonawala D, Verdijk P, Wijmenga-Monsuur AJ, Boog CJ, Koedam P, Visser LG, Rots NY. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine 2013;31:3688-94. [PMID: 23770332 DOI: 10.1016/j.vaccine.2013.05.104] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
17 Nelson KS, Janssen JM, Troy SB, Maldonado Y. Intradermal fractional dose inactivated polio vaccine: A review of the literature. Vaccine 2012;30:121-5. [DOI: 10.1016/j.vaccine.2011.11.018] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
18 Ambrón LL, Torres LIE, Carreras AP, Santana BMG, Sardiña MÁG, Aguirre SR, Fuentes AT. [Cuban experience in immunization, 1962-2016Experiência cubana em imunização, 1962-2016]. Rev Panam Salud Publica 2018;42:e34. [PMID: 31093063 DOI: 10.26633/RPSP.2018.34] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Anand A, Molodecky NA, Pallansch MA, Sutter RW. Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule. Vaccine 2017;35:2993-8. [PMID: 28434691 DOI: 10.1016/j.vaccine.2017.03.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
20 Resik S, Tejeda A, Diaz M, Okayasu H, Sein C, Molodecky NA, Fonseca M, Alemany N, Garcia G, Hung LH, Martinez Y, Sutter RW. Boosting Immune Responses Following Fractional-Dose Inactivated Poliovirus Vaccine: A Randomized, Controlled Trial. J Infect Dis 2017;215:175-82. [PMID: 28073858 DOI: 10.1093/infdis/jiw492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
21 Grassly NC. The final stages of the global eradication of poliomyelitis. Philos Trans R Soc Lond B Biol Sci 2013;368:20120140. [PMID: 23798688 DOI: 10.1098/rstb.2012.0140] [Cited by in Crossref: 51] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
22 Gamazo C, Pastor Y, Larrañeta E, Berzosa M, Irache JM, Donnelly RF. Understanding the basis of transcutaneous vaccine delivery. Ther Deliv 2019;10:63-80. [PMID: 30730825 DOI: 10.4155/tde-2018-0054] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
23 Hickling JK, Jones KR, Friede M, Zehrung D, Chen D, Kristensen D. Intradermal delivery of vaccines: potential benefits and current challenges. Bull World Health Organ 2011;89:221-6. [PMID: 21379418 DOI: 10.2471/BLT.10.079426] [Cited by in Crossref: 106] [Cited by in F6Publishing: 46] [Article Influence: 10.6] [Reference Citation Analysis]
24 Muller DA, Fernando GJP, Owens NS, Agyei-Yeboah C, Wei JCJ, Depelsenaire ACI, Forster A, Fahey P, Weldon WC, Oberste MS, Young PR, Kendall MAF. High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses. Sci Rep 2017;7:12644. [PMID: 28974777 DOI: 10.1038/s41598-017-13011-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
25 Criscuolo E, Caputo V, Diotti RA, Sautto GA, Kirchenbaum GA, Clementi N. Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines. J Immunol Res 2019;2019:8303648. [PMID: 30949518 DOI: 10.1155/2019/8303648] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 14.5] [Reference Citation Analysis]
26 Yan S, Chen H, Zhang Z, Chang S, Xiao Y, Luo L, Zhang Z, Sun L, Chen X, Yang Y, Shi X, Guo Y, Sun Y, Li H, Li N, Han S, Ma M, Yang X. Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China. Vaccine 2020;38:6274-9. [PMID: 32747216 DOI: 10.1016/j.vaccine.2020.07.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Vidor E, Plotkin SA. Poliovirus vaccine—inactivated. Vaccines. Elsevier; 2013. pp. 573-97. [DOI: 10.1016/b978-1-4557-0090-5.00034-3] [Cited by in Crossref: 25] [Article Influence: 3.1] [Reference Citation Analysis]
28 Mangal TD, Aylward RB, Grassly NC. The Potential Impact of Routine Immunization with Inactivated Poliovirus Vaccine on Wild-type or Vaccine-derived Poliovirus Outbreaks in a Posteradication Setting. American Journal of Epidemiology 2013;178:1579-87. [DOI: 10.1093/aje/kwt203] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
29 O'Ryan M, Bandyopadhyay AS, Villena R, Espinoza M, Novoa J, Weldon WC, Oberste MS, Self S, Borate BR, Asturias EJ, Clemens R, Orenstein W, Jimeno J, Rüttimann R, Costa Clemens SA; Chilean IPV/bOPV study group. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis 2015;15:1273-82. [PMID: 26318714 DOI: 10.1016/S1473-3099(15)00219-4] [Cited by in Crossref: 45] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
30 Verdijk P, Rots NY, Bakker WA. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Review of Vaccines 2014;10:635-44. [DOI: 10.1586/erv.11.51] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
31 Bullo UF, Mehraj J, Raza SM, Rasool S, Ansari NN, Shaikh AA, Phul ZA, Memon SA, Baloch RI, Baloch ZA, Chandio SA. An experience of mass administration of fractional dose inactivated polio vaccine through intradermal needle-free injectors in Karachi, Sindh, Pakistan. BMC Public Health 2021;21:44. [PMID: 33407294 DOI: 10.1186/s12889-020-10041-8] [Reference Citation Analysis]
32 Okayasu H, Sein C, Chang Blanc D, Gonzalez AR, Zehrung D, Jarrahian C, Macklin G, Sutter RW. Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization. J Infect Dis 2017;216:S161-7. [PMID: 28838185 DOI: 10.1093/infdis/jix038] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
33 Okayasu H, Sutter RW, Jafari HS, Takane M, Aylward RB. Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis 2014;210 Suppl 1:S459-64. [PMID: 25316868 DOI: 10.1093/infdis/jiu128] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
34 Gratieri T, Alberti I, Lapteva M, Kalia YN. Next generation intra- and transdermal therapeutic systems: using non- and minimally-invasive technologies to increase drug delivery into and across the skin. Eur J Pharm Sci. 2013;50:609-622. [PMID: 23567467 DOI: 10.1016/j.ejps.2013.03.019] [Cited by in Crossref: 72] [Cited by in F6Publishing: 42] [Article Influence: 9.0] [Reference Citation Analysis]
35 Sanchez-Schmitz G, Levy O. Development of newborn and infant vaccines. Sci Transl Med 2011;3:90ps27. [PMID: 21734174 DOI: 10.1126/scitranslmed.3001880] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
36 Saleem AF, Mach O, Yousafzai MT, Khan A, Weldon WC, Oberste MS, Sutter RW, Zaidi AKM. Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan. Vaccine 2017;35:3209-14. [PMID: 28479178 DOI: 10.1016/j.vaccine.2017.04.075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
37 Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim JH, Cochi SL. Preeradication vaccine policy options for poliovirus infection and disease control. Risk Anal 2013;33:516-43. [PMID: 23461599 DOI: 10.1111/risa.12019] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
38 Shulman LM. Polio and Its Epidemiology. In: Kanki P, Grimes DJ, editors. Infectious Diseases. New York: Springer; 2013. pp. 237-308. [DOI: 10.1007/978-1-4614-5719-0_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Ma L, Cai W, Sun M, Cun Y, Zhou J, Liu J, Hu W, Zhang X, Song S, Jiang S, Liao G. Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats. Hum Vaccin Immunother 2016;12:3125-31. [PMID: 27558963 DOI: 10.1080/21645515.2016.1214347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
40 Thompson KM, Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. Expert Rev Vaccines 2012;11:449-59. [PMID: 22551030 DOI: 10.1586/erv.11.195] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
41 Louis L, Clark M, Wise MC, Glennie N, Wong A, Broderick K, Uzonna J, Weiner DB, Scott P. Intradermal Synthetic DNA Vaccination Generates Leishmania-Specific T Cells in the Skin and Protection against Leishmania major. Infect Immun 2019;87:e00227-19. [PMID: 31182618 DOI: 10.1128/IAI.00227-19] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
42 Hettinga J, Carlisle R. Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects. Vaccines (Basel) 2020;8:E534. [PMID: 32947966 DOI: 10.3390/vaccines8030534] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
43 Schnyder JL, De Pijper CA, Garcia Garrido HM, Daams JG, Goorhuis A, Stijnis C, Schaumburg F, Grobusch MP. Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis. Travel Med Infect Dis. 2020;37:101868. [PMID: 32898704 DOI: 10.1016/j.tmaid.2020.101868] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
44 Behrend MR, Hu H, Nigmatulina KR, Eckhoff P. A quantitative survey of the literature on poliovirus infection and immunity. Int J Infect Dis 2014;18:4-13. [PMID: 24246740 DOI: 10.1016/j.ijid.2013.09.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
45 Duintjer Tebbens RJ, Thompson KM. Poliovirus vaccination during the endgame: insights from integrated modeling. Expert Review of Vaccines 2017;16:577-86. [DOI: 10.1080/14760584.2017.1322514] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
46 Sellers RS, Nelson K, Bennet B, Wolf J, Tripathi N, Chamanza R, Perron Lepage MF, Adkins K, Laurent S, Troth SP. Scientific and Regulatory Policy Committee Points to Consider*: Approaches to the Conduct and Interpretation of Vaccine Safety Studies for Clinical and Anatomic Pathologists. Toxicol Pathol 2020;48:257-76. [PMID: 31594486 DOI: 10.1177/0192623319875085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
47 Migliore A, Gigliucci G, Di Marzo R, Russo D, Mammucari M. Intradermal Vaccination: A Potential Tool in the Battle Against the COVID-19 Pandemic? Risk Manag Healthc Policy 2021;14:2079-87. [PMID: 34045909 DOI: 10.2147/RMHP.S309707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
48 Anand A, Zaman K, Estívariz CF, Yunus M, Gary HE, Weldon WC, Bari TI, Steven Oberste M, Wassilak SG, Luby SP, Heffelfinger JD, Pallansch MA. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. Vaccine 2015;33:6816-22. [PMID: 26476367 DOI: 10.1016/j.vaccine.2015.09.039] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 10.3] [Reference Citation Analysis]
49 Vidor E. Poliovirus Vaccine–Inactivated. Plotkin's Vaccines. Elsevier; 2018. pp. 841-865.e10. [DOI: 10.1016/b978-0-323-35761-6.00047-x] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
50 Mustafa MS, Rastogi V, Singh PMP. Polio switch strategy: An obituary in the making? Med J Armed Forces India 2021;77:125-8. [PMID: 33867626 DOI: 10.1016/j.mjafi.2020.07.005] [Reference Citation Analysis]
51 Hamidi A, Bakker WA. Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains. Pharm Pat Anal 2012;1:589-99. [PMID: 24236927 DOI: 10.4155/ppa.12.70] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
52 Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication. Expert Rev Vaccines 2014;13:221-34. [PMID: 24308581 DOI: 10.1586/14760584.2014.864563] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
53 Engelke L, Winter G, Hook S, Engert J. Recent insights into cutaneous immunization: How to vaccinate via the skin. Vaccine 2015;33:4663-74. [PMID: 26006087 DOI: 10.1016/j.vaccine.2015.05.012] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 9.5] [Reference Citation Analysis]
54 Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. Polio vaccination: past, present and future. Future Microbiol. 2015;10:791-808. [PMID: 25824845 DOI: 10.2217/fmb.15.19] [Cited by in Crossref: 115] [Cited by in F6Publishing: 89] [Article Influence: 19.2] [Reference Citation Analysis]
55 Cadorna-Carlos J, Vidor E, Bonnet MC. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int J Infect Dis 2012;16:e110-6. [PMID: 22153001 DOI: 10.1016/j.ijid.2011.10.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
56 Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 2012;8:e1002599. [PMID: 22532797 DOI: 10.1371/journal.ppat.1002599] [Cited by in Crossref: 131] [Cited by in F6Publishing: 103] [Article Influence: 14.6] [Reference Citation Analysis]
57 Grassly NC. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis 2014;210 Suppl 1:S439-46. [PMID: 24634499 DOI: 10.1093/infdis/jit601] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
58 Jarrahian C, Rein-Weston A, Saxon G, Creelman B, Kachmarik G, Anand A, Zehrung D. Vial usage, device dead space, vaccine wastage, and dose accuracy of intradermal delivery devices for inactivated poliovirus vaccine (IPV). Vaccine 2017;35:1789-96. [PMID: 28189403 DOI: 10.1016/j.vaccine.2016.11.098] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
59 Cramer JP, Jimeno J, Han HH, Lin S, Hartmann K, Borkowski A, Sáez-Llorens X. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial. Vaccine 2020;38:5313-23. [PMID: 32563609 DOI: 10.1016/j.vaccine.2020.05.081] [Reference Citation Analysis]
60 Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010;172:1213-29. [PMID: 20978089 DOI: 10.1093/aje/kwq320] [Cited by in Crossref: 243] [Cited by in F6Publishing: 158] [Article Influence: 22.1] [Reference Citation Analysis]
61 Coughlin MM, Collins M, Saxon G, Jarrahian C, Zehrung D, Cappello C, Dhere R, Royals M, Papania M, Rota PA. Effect of jet injection on infectivity of measles, mumps, and rubella vaccine in a bench model. Vaccine 2015;33:4540-7. [DOI: 10.1016/j.vaccine.2015.07.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
62 Levin Y, Kochba E, Hung I, Kenney R. Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future. Hum Vaccin Immunother 2015;11:991-7. [PMID: 25745830 DOI: 10.1080/21645515.2015.1010871] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 9.6] [Reference Citation Analysis]
63 Schipper P, van der Maaden K, Romeijn S, Oomens C, Kersten G, Jiskoot W, Bouwstra J. Repeated fractional intradermal dosing of an inactivated polio vaccine by a single hollow microneedle leads to superior immune responses. J Control Release 2016;242:141-7. [PMID: 27496634 DOI: 10.1016/j.jconrel.2016.07.055] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
64 Delgado-Charro MB, Guy RH. Effective use of transdermal drug delivery in children. Adv Drug Deliv Rev 2014;73:63-82. [PMID: 24333231 DOI: 10.1016/j.addr.2013.11.014] [Cited by in Crossref: 48] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
65 Muller DA, Pearson FE, Fernando GJ, Agyei-Yeboah C, Owens NS, Corrie SR, Crichton ML, Wei JC, Weldon WC, Oberste MS, Young PR, Kendall MA. Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses. Sci Rep 2016;6:22094. [PMID: 26911254 DOI: 10.1038/srep22094] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
66 Chen H, Gao Z, Bai S, Liu X, Han S, Xiao Y, Liu F, Yu Y, Sun H, Yang X. Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement. Vaccine 2021;39:2467-74. [PMID: 33810904 DOI: 10.1016/j.vaccine.2021.02.073] [Reference Citation Analysis]
67 Baicus A. History of polio vaccination. World J Virol 2012;1:108-14. [PMID: 24175215 DOI: 10.5501/wjv.v1.i4.108] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
68 Hegde NR, Kaveri SV, Bayry J. Recent advances in the administration of vaccines for infectious diseases: microneedles as painless delivery devices for mass vaccination. Drug Discovery Today 2011;16:1061-8. [DOI: 10.1016/j.drudis.2011.07.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
69 Brickley EB, Wright PF. Maximising the impact of inactivated polio vaccines. Lancet Infect Dis 2017;17:680-1. [PMID: 28454675 DOI: 10.1016/S1473-3099(17)30236-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
70 Kis EE, Winter G, Myschik J. Devices for intradermal vaccination. Vaccine 2012;30:523-38. [DOI: 10.1016/j.vaccine.2011.11.020] [Cited by in Crossref: 67] [Cited by in F6Publishing: 47] [Article Influence: 7.4] [Reference Citation Analysis]
71 Yousafzai MT, Saleem AF, Mach O, Baig A, Sutter RW, Zaidi AKM. Feasibility of conducting intradermal vaccination campaign with inactivated poliovirus vaccine using Tropis intradermal needle free injection system, Karachi, Pakistan. Heliyon 2017;3:e00395. [PMID: 29333501 DOI: 10.1016/j.heliyon.2017.e00395] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
72 Kraan H, van der Stel W, Kersten G, Amorij J. Alternative administration routes and delivery technologies for polio vaccines. Expert Review of Vaccines 2016;15:1029-40. [DOI: 10.1586/14760584.2016.1158650] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
73 Estívariz CF, Jafari H, Sutter RW, John TJ, Jain V, Agarwal A, Verma H, Pallansch MA, Singh AP, Guirguis S, Awale J, Burton A, Bahl S, Chatterjee A, Aylward RB. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6–9 months in Moradabad, India: a community-based, randomised controlled trial. The Lancet Infectious Diseases 2012;12:128-35. [DOI: 10.1016/s1473-3099(11)70190-6] [Cited by in Crossref: 76] [Cited by in F6Publishing: 26] [Article Influence: 8.4] [Reference Citation Analysis]
74 Rivera L, Pedersen RS, Peña L, Olsen KJ, Andreasen LV, Kromann I, Nielsen PI, Sørensen C, Dietrich J, Bandyopadhyay AS, Thierry-Carstensen B. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial. Lancet Infect Dis 2017;17:745-53. [PMID: 28454674 DOI: 10.1016/S1473-3099(17)30177-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
75 Baldwin SL, Fox CB, Pallansch MA, Coler RN, Reed SG, Friede M. Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine 2011;29:644-9. [DOI: 10.1016/j.vaccine.2010.11.043] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
76 Clarke E, Saidu Y, Adetifa JU, Adigweme I, Hydara MB, Bashorun AO, Moneke-Anyanwoke N, Umesi A, Roberts E, Cham PM, Okoye ME, Brown KE, Niedrig M, Chowdhury PR, Clemens R, Bandyopadhyay AS, Mueller J, Jeffries DJ, Kampmann B. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia. Lancet Glob Health 2016;4:e534-47. [PMID: 27364568 DOI: 10.1016/S2214-109X(16)30075-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 5.4] [Reference Citation Analysis]
77 Schipper P, van der Maaden K, Romeijn S, Oomens C, Kersten G, Jiskoot W, Bouwstra J. Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles. Pharm Res 2016;33:2269-79. [PMID: 27317570 DOI: 10.1007/s11095-016-1965-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
78 Troy SB, Kouiavskaia D, Siik J, Kochba E, Beydoun H, Mirochnitchenko O, Levin Y, Khardori N, Chumakov K, Maldonado Y. Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults. J Infect Dis 2015;211:1969-76. [PMID: 25567841 DOI: 10.1093/infdis/jiu841] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
79 Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine—live. Vaccines. Elsevier; 2013. pp. 598-645. [DOI: 10.1016/b978-1-4557-0090-5.00035-5] [Cited by in Crossref: 36] [Article Influence: 4.5] [Reference Citation Analysis]